In Simple Terms
Alnylam’s business was growing, helped by sales of a heart-disease treatment called Amvuttra. In August 2025, a writer wondered whether the company might soon be worth as much as Vertex, even though the two companies do not compete directly. A later article revisited that prediction, but the information available here does not say whether it came true.
A Forecast Built on Fast Growth
On August 7, 2025, Adam Feuerstein pointed to Alnylam’s accelerating growth and linked it to sales of Amvuttra, which he described as a commercial success in treating cardiomyopathy. At the time, the figures he cited put Alnylam’s market value at about $60 billion, compared with roughly $100 billion for Vertex. The gap was substantial, but that did not stop him from asking whether Alnylam could catch up in market value.
Those figures describe the companies’ estimated market values when the idea was raised. They are not the companies’ revenues, nor do they show how much the drug had sold. The available text also calls Alnylam’s growth rapid without giving a specific growth rate or a quarterly or annual comparison. The forecast should therefore be understood as a view of a general trend, not a calculation that can be checked in detail using this information alone.
Amvuttra matters here because it was identified as a contributor to Alnylam’s growth. When a treatment becomes an important business driver, investors may revise their expectations about a company’s ability to expand and generate future returns. But that does not mean one drug automatically guarantees continued growth or that the company’s market value will keep rising. Expectations can change, and market value itself moves with investors’ views of the future.
A Comparison of Company Values, Not Products
Feuerstein emphasized that Alnylam and Vertex are not direct competitors. That distinction is essential to understanding the comparison: the claim is not that the companies sell the same treatment or compete for the same patients. Instead, it puts their market values side by side and asks whether Alnylam’s rise could make it comparable to Vertex in investors’ eyes in terms of market value.
Market value is not a medical measure of a treatment’s effectiveness, nor does it indicate how important a disease is or how much priority it should receive. It is a financial estimate shaped by investors’ expectations for a company. That value can rise or fall even when the number of patients receiving a treatment has not changed at that moment. So the comparison between $60 billion and $100 billion should not be read as a comparison of Amvuttra’s quality with Vertex’s medicines, or of treatment outcomes that the text does not mention.
Likewise, approaching another company’s value does not, by itself, prove that a business trajectory is more durable. Market value is one indicator in a broader picture. Assessing a forecast also requires details such as actual sales figures and how they change, whether demand is likely to last, and what later financial expectations look like. Those details are absent from the available excerpt, so it cannot confirm that Alnylam overtook Vertex or even that it has actually drawn close to it.
Why the Forecast Is Hard to Test
Any forecast about growth at a drug company raises two different questions. The first concerns the medicine itself: will it continue to drive sales over time? The second is about how that business activity translates into a value investors consider appropriate for the company. A treatment’s commercial performance may matter a great deal, but the eventual market response does not necessarily follow a predictable or guaranteed path.
In Alnylam’s case, the available text makes a clear connection between the company’s growth and Amvuttra sales, but it does not provide enough data to measure the drug’s contribution or how long it might last. The excerpt does not give the sales figure, what share of Alnylam’s total business those sales represent, or whether sales growth exceeded management’s or investors’ expectations. Without those numbers, it is more accurate to describe the idea as a bet on continued commercial momentum than as a proven result or a settled forecast.
The excerpt also does not define exactly what “in the near future” means. Timing is an important part of any financial prediction: reaching a comparable value in months is different from doing so over years, and reaching it temporarily is not the same as holding it. No timeframe or numerical trajectory should be added when the source does not provide one. All we know is that in August 2025, Feuerstein saw a possibility that Alnylam’s growth rate could bring its market value up to Vertex’s—or push it higher—before long.
Revisiting the Forecast Later
In a piece dated November 12, 2026, Feuerstein returned to his earlier forecast and presented the revisit as an exercise in accountability. That matters because it puts the original opinion in the right context: what he said in August 2025 was not an established fact, but a prediction about the future that could later be checked. However, the excerpt available here does not show the result of that check. It stops after providing background on the forecast and gives neither the companies’ newer market values nor an answer to whether Alnylam caught up with Vertex.
It would therefore be wrong to treat the mere fact that the subject was reopened in November 2026 as evidence that the forecast succeeded or failed. The follow-up raises the question, but the available text does not answer it. Any claim about the companies’ relative rankings at that date, or about how much their values had changed, would require information that is not included here. Distinguishing what we know from what we do not know is part of responsible reading of financial news about medicine and biotechnology.
Accountability also means more than acknowledging an earlier forecast. It requires comparing the prediction with the outcome, examining the assumptions behind it, and explaining what changed if the expected path did not materialize. But that comparison cannot be completed without later data. The available information establishes a starting point: a forecast made on August 7, 2025; approximate market values for the two companies at the time; and a growth driver attributed to Amvuttra sales. The excerpt does not include the outcome.
What This Story Says About Drugs and Markets
This case shows how a treatment’s commercial success can become part of a broader discussion about the position of the company that developed it. In this context, the treatment is more than a product: its performance may influence how investors imagine the company’s future. But moving from strong sales for a treatment to a prediction that the company’s value will double or surpass that of a larger competitor is not automatic. It depends on expectations, sustained performance, and figures that the available text does not provide.
The comparison also serves as a reminder that market language can reduce different drug companies to a single number: market value. That figure can help show how investors assess a company’s scale, but it cannot explain the nature of its treatments or the medical value of its work. Nor does it tell us whether two companies operate in the same therapeutic area. That is why the reminder that Alnylam and Vertex are not direct competitors matters: this is a financial comparison, not a showdown between two drugs.
As for Amvuttra, the specific information in the text is that its sales were associated with Alnylam’s accelerating growth and that it is a treatment for cardiomyopathy. The excerpt does not describe how the drug works, what clinical trials found, or what kinds of patients use it. Adding medical details beyond those facts would go beyond the information available. The central point is still clear: a drug’s commercial success can raise expectations for its company, but it cannot by itself guarantee a particular market value.
The Bottom Line
The story began with Alnylam’s growth, which was linked to sales of Amvuttra, a treatment for cardiomyopathy. That led to a question: could Alnylam’s market value rival Vertex’s? On August 7, 2025, the figures cited were about $60 billion for Alnylam and $100 billion for Vertex, with an important caveat that the companies are not direct competitors. Feuerstein revisited the forecast on November 12, 2026, but the available excerpt does not reveal the outcome or the companies’ more recent values. The case illustrates the difference between an intriguing financial prediction and a result that cannot be established without clear follow-up data.